Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Combined administration of muscarinic receptor antagonists and group II/III metabotropic glutamate (mGlu) receptor ligands as a novel efficacious method to treat depression - the preclinical studies

2020/37/B/NZ7/03499

Keywords:

Depression scopolamine muscarinic receptors M1 receptors M2 receptors M3 receptors M4 receptors M5 receptors metabotropic receptors for glutamate mGlu2 receptors mGlu3 receptors mGlu7 receptors antidepressant effects

Descriptors:

  • NZ7_014:
  • NZ5_007:

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

woj. małopolskie

Other projects carried out by the institution 

Principal investigator (from the host institution):

prof. Andrzej Mikołaj Pilc 

Number of co-investigators in the project: 6

Call: OPUS 19 - announced on 2020-03-16

Amount awarded: 2 980 248 PLN

Project start date (Y-m-d): 2021-01-14

Project end date (Y-m-d): 2026-01-13

Project duration:: 60 months (the same as in the proposal)

Project status: Pending project

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

  • Publication in academic press/journals (4)
  1. Interaction of hallucinogenic rapid‑acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies
    Authors:
    Barbara Chruścicka‑Smaga, · Agata Machaczka, · Bernadeta Szewczyk, · Andrzej Pilc
    Academic press:
    Pharmacological Reports (rok: 2023, tom: 75/6, strony: 1341-1349), Wydawca: Springer
    Status:
    Published
    DOI:
    10.1007/s43440-023-00547-4 - link to the publication
  2. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
    Authors:
    Pilc, A., Machaczka, A., Kawalec, P., Smith, J.L., Witkin, J.M.
    Academic press:
    Expert Opinion on Drug Discovery (rok: 2022, tom: 17-10, strony: 1131-1146), Wydawca: Taylor&Francis
    Status:
    Published
    DOI:
    10.1080/17460441.2022.2111415 - link to the publication
  3. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
    Authors:
    Pilc, A., Machaczka, A., Kawalec, P., Smith, J.L., Witkin, J.M.
    Academic press:
    Expert Opinion on Drug Discovery (rok: 2022, tom: 17-10, strony: 1131-1146), Wydawca: Taylor&Francis
    Status:
    Published
    DOI:
    10.1080/17460441.2022.2111415 - link to the publication
  4. The Potential of Scopolamine as an Antidepressant in Major Depressive Disorder: A Systematic Review of Randomized Controlled Trials
    Authors:
    Paweł Mocko, Katarzyna ´ Sladowska, Paweł Kawalec, Yana Babii and Andrzej Pilc
    Academic press:
    Biomedicines (rok: 2023, tom: 11, strony: 45669), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/biomedicines11102636 - link to the publication

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy